Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

The role of type 1 interferons in coagulation induced by gram-negative bacteria

Xinyu Yang, Xiaoye Cheng, Yiting Tang, Xianhui Qiu, Zhongtai Wang, Guang Fu, Jianfeng Wu, Haixia Kang, Jing Wang, Haichao Wang, Fangping Chen, Xianzhong Xiao, Timothy R. Billiar, Ben Lu

Blood (2020) 135 (14): 1087–1100.

https://doi.org/10.1182/blood.2019002282

Published: 2020

Includes: Multimedia, Supplemental data

Journal Articles

Altered Iron Metabolism Is a New Targetable Hallmark for Multiple Myeloma

Can Li, MD, Xuelian Tan, Qierra Brockman, BA, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Marta Chesi, PhD, P. Leif Bergsagel, MD, Fangping Chen, MD PhD, Ivana Frech, DSc, PhD MBA, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 3059.

https://doi.org/10.1182/blood-2019-123473

Published: 2019

Journal Articles

TRIP13 Modulates Protein Deubiquitination to Promote Myeloma Progression

Can Li, MD, Reinaldo Franqui-Machin, Jiliang Xia, PhD, Gregory S. Thomas, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Fangping Chen, MD PhD, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 854.

https://doi.org/10.1182/blood-2019-123818

Published: 2019

Journal Articles

Post-Transplantation Cyclophosphamide and Short-Term Methotrexate for Tolerance Induction in HLA-Haploidentical Transplantation for Severe Aplastic Anemia

Bin Fu, MD, Yajing Xu, MD PhD, Yan Chen, MD PhD, Fangping Chen, MD PhD

Blood (2017) 130 (Supplement 1): 3237.

https://doi.org/10.1182/blood.V130.Suppl_1.3237.3237

Published: 2017

Journal Articles

NKG2D Negatively Regulates CD4 T Cells in Allo-Response in Mice

Mengmeng Zhang, MD, Yongxia Wu, PhD MD, David Bastian, Hung D Nguyen, PhD, Supinya Iamsawat, MSc, Anusara Daenthanasanmak, Fangping Chen, MD PhD, Xue-Zhong Yu, MD MS

Blood (2017) 130 (Supplement 1): 2279.

https://doi.org/10.1182/blood.V130.Suppl_1.2279.2279

Published: 2017

Journal Articles

Long-Term Use of Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Chinese Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): MM-024 Expanded Access Program (EAP)

Xin Du, MD, Jie Jin, MD, Zhen Cai, MD, Fangping Chen, MD, Dao-bin Zhou, MD, Li Yu, MD, Xiaoyan Ke, MD PhD, Xiao Li, MD PhD, Depei Wu, MD, Fanyi Meng, MD, Dena DeMarco, Jingshan Zhang, PhD, Jay Mei, MD, Jian Hou, MD PhD

Blood (2014) 124 (21): 5737.

https://doi.org/10.1182/blood.V124.21.5737.5737

Published: 2014

Journal Articles

The MM-021 Trial Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma: Impact Of Prior Therapies On Efficacy and Safety

Jie Jin, MD, Xin Du, MD, Zhen Cai, MD, Fangping Chen, MD, Dao-bin Zhou, MD, Li Yu, MD, Xiao Li, MD, PhD, Depei Wu, MD, Fanyi Meng, MD, Huisheng Ai, MMed, Jianmin Wang, MD, Jingshan Zhang, PhD, Honeylet Wortman-Vayn, Jay Mei, MD, Jian Hou, MD, PhD

Blood (2013) 122 (21): 3227.

https://doi.org/10.1182/blood.V122.21.3227.3227

Published: 2013

Journal Articles

Efficacy and Safety Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment: MM-021 Subgroup Analysis

Dao-bin Zhou, MD, Li Yu, MD, Xin Du, MD, Jie Jin, MD, Zhen Cai, MD, Fangping Chen, MD, Xiao Li, MD, PhD, Depei Wu, MD, Fanyi Meng, MD, Huisheng Ai, MMed, Jingshan Zhang, PhD, Honeylet Wortman-Vayn, Jay Mei, MD, Jianmin Wang, MD, Jian Hou, MD, PhD

Blood (2013) 122 (21): 5374.

https://doi.org/10.1182/blood.V122.21.5374.5374

Published: 2013

Journal Articles

A Multi-Center, Open-Label Phase II Study of Lenalidomide Plus Low-Dose Dexamethasone in Chinese Patients with Relapsed/Refractory Multiple Myeloma - the MM-021 Trial

Jian Hou, MD, PhD, Jie Jin, MD, Zhen Cai, Fangping Chen, Li Yu, Dao-bin Zhou, MD, Xiao Li, MD, PhD, Xiaoyan Ke, MD, PhD, Depei Wu, MD, Huisheng Ai, Fanyi Meng, MD, Jianmin Wang, Jay Mei, MD, PhD, Jingshan Zhang, PhD, Honeylet Wortman-Vayn, Xin Du, PhD

Blood (2012) 120 (21): 1864.

https://doi.org/10.1182/blood.V120.21.1864.1864

Published: 2012

Journal Articles

Inhibition of the mTORC2 and chaperone pathways to treat leukemia

Fan Zhang, Adam S. Lazorchak, Dou Liu, Fangping Chen, Bing Su

Blood (2012) 119 (25): 6080–6088.

https://doi.org/10.1182/blood-2011-12-399519

Published: 2012

Journal Articles

A Multicenter, Open-Label Study of Posaconazole Oral Suspension in Treatment of Patients with Invasive Fungal Infection Refractory to or Intolerant of First-Line Therapy,

Xiaojun Huang, Fengrong Wang, Yuhong Chen, MD, PhD, Ting Liu, MD, Jianxiang Wang, MD, Jianda Hu, PhD, Jie Jin, MD, Fangping Chen, Shujie Wang, MD, PhD, Zhixiang Shen, MD, PhD, Li Yu, Kang Yu, Yingmin Liang

Blood (2011) 118 (21): 3241.

https://doi.org/10.1182/blood.V118.21.3241.3241

Published: 2011

Journal Articles

A naturally occurring mutation near the amino terminus of αIIb defines a new region involved in ligand binding to αIIbβ3

Ramesh B. Basani, Deborah L. French, Gaston Vilaire, Deborah L. Brown, Fangping Chen, Barry S. Coller, Jerry M. Derrick, T. Kent Gartner, Joel S. Bennett, Mortimer Poncz

Blood (2000) 95 (1): 180–188.

https://doi.org/10.1182/blood.V95.1.180

Published: 2000

Journal Articles

Glycoprotein IIb Leu214Pro Mutation Produces Glanzmann Thrombasthenia With Both Quantitative and Qualitative Abnormalities in GPIIb/IIIa

Christine M. Grimaldi, Fangping Chen, Changhong Wu, Harvey J. Weiss, Barry S. Coller, Deborah L. French

Blood (1998) 91 (5): 1562–1571.

https://doi.org/10.1182/blood.V91.5.1562

Published: 1998

NARROW

The role of type 1 interferons in coagulation induced by gram-negative bacteria

Altered Iron Metabolism Is a New Targetable Hallmark for Multiple Myeloma

TRIP13 Modulates Protein Deubiquitination to Promote Myeloma Progression

Post-Transplantation Cyclophosphamide and Short-Term Methotrexate for Tolerance Induction in HLA-Haploidentical Transplantation for Severe Aplastic Anemia

NKG2D Negatively Regulates CD4 T Cells in Allo-Response in Mice

Long-Term Use of Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Chinese Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): MM-024 Expanded Access Program (EAP)

The MM-021 Trial Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma: Impact Of Prior Therapies On Efficacy and Safety

Efficacy and Safety Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment: MM-021 Subgroup Analysis

A Multi-Center, Open-Label Phase II Study of Lenalidomide Plus Low-Dose Dexamethasone in Chinese Patients with Relapsed/Refractory Multiple Myeloma - the MM-021 Trial

Inhibition of the mTORC2 and chaperone pathways to treat leukemia

A Multicenter, Open-Label Study of Posaconazole Oral Suspension in Treatment of Patients with Invasive Fungal Infection Refractory to or Intolerant of First-Line Therapy,

A naturally occurring mutation near the amino terminus of αIIb defines a new region involved in ligand binding to αIIbβ3

Glycoprotein IIb Leu214Pro Mutation Produces Glanzmann Thrombasthenia With Both Quantitative and Qualitative Abnormalities in GPIIb/IIIa

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only